Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appe...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00819/full |
| _version_ | 1818577524037255168 |
|---|---|
| author | David Arias Ron Carmen M. Labandeira María Carmen Areses Manrique Paula Sampedro Domarco Ihab Abdulkader Jesús García-Mata Christian Rolfo Diego González-Rivas Diego González-Rivas Jose Luis Fírvida |
| author_facet | David Arias Ron Carmen M. Labandeira María Carmen Areses Manrique Paula Sampedro Domarco Ihab Abdulkader Jesús García-Mata Christian Rolfo Diego González-Rivas Diego González-Rivas Jose Luis Fírvida |
| author_sort | David Arias Ron |
| collection | DOAJ |
| description | In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI. |
| first_indexed | 2024-12-16T06:31:17Z |
| format | Article |
| id | doaj.art-0227a4fb32734cf9aced213326d3f9b3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T06:31:17Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0227a4fb32734cf9aced213326d3f9b32022-12-21T22:40:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00819480245Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case ReportDavid Arias Ron0Carmen M. Labandeira1María Carmen Areses Manrique2Paula Sampedro Domarco3Ihab Abdulkader4Jesús García-Mata5Christian Rolfo6Diego González-Rivas7Diego González-Rivas8Jose Luis Fírvida9Medical Oncology Department, University Hospital Complex of Ourense, Ourense, SpainNeurology Department, University Hospital Complex of Vigo, Hospital Alvaro Cunqueiro, Pontevedra, SpainMedical Oncology Department, University Hospital Complex of Ourense, Ourense, SpainMedical Oncology Department, University Hospital Complex of Ourense, Ourense, SpainAnatomopathology Department, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, SpainMedical Oncology Department, University Hospital Complex of Ourense, Ourense, SpainThoracic Medical Oncology, Early Clinical Trials, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United StatesThoracic Surgery Department, Hospital San Rafael, Coruña, SpainDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, ChinaMedical Oncology Department, University Hospital Complex of Ourense, Ourense, SpainIn a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI.https://www.frontiersin.org/article/10.3389/fonc.2019.00819/fullsquamous lung cancernivolumableptomeningeal carcinomatosisPD-L1complete response |
| spellingShingle | David Arias Ron Carmen M. Labandeira María Carmen Areses Manrique Paula Sampedro Domarco Ihab Abdulkader Jesús García-Mata Christian Rolfo Diego González-Rivas Diego González-Rivas Jose Luis Fírvida Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report Frontiers in Oncology squamous lung cancer nivolumab leptomeningeal carcinomatosis PD-L1 complete response |
| title | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report |
| title_full | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report |
| title_fullStr | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report |
| title_full_unstemmed | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report |
| title_short | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report |
| title_sort | dramatic response of leptomeningeal carcinomatosis to nivolumab in pd l1 highly expressive non small cell lung cancer a case report |
| topic | squamous lung cancer nivolumab leptomeningeal carcinomatosis PD-L1 complete response |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00819/full |
| work_keys_str_mv | AT davidariasron dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT carmenmlabandeira dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT mariacarmenaresesmanrique dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT paulasampedrodomarco dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT ihababdulkader dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT jesusgarciamata dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT christianrolfo dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT diegogonzalezrivas dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT diegogonzalezrivas dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport AT joseluisfirvida dramaticresponseofleptomeningealcarcinomatosistonivolumabinpdl1highlyexpressivenonsmallcelllungcanceracasereport |